II. Epidemiology

  1. Under-Vaccination despite high efficacy and potential to prevent anogenital and oropharyngeal cancer
    1. Girls: 57.3% vaccinated (as of 2013 in U.S.)
    2. Boys: 34.6% vaccinated (as of 2013 in U.S.)

III. Indications

  1. General indications
    1. Prevention of Cervical Dysplasia
    2. Prevention of anal cancer (receptive anal intercourse)
  2. Girls and women: Part of Primary Series
    1. Females routinely at age 11-12 and catch-up age <26 years
    2. Vaccination may start as early as age 9 years
  3. Boys and men
    1. Part of Primary Series in United States as of 2012
    2. Males routinely at age 11 to 12 years and catch-up age 21 years
    3. Routine use in males ages 22 to 26 years old who have HIV Infection or who have sex with men
    4. Permissive use of Vaccine in males ages 22 to 26 years old
    5. Reduces risk of Genital Warts, precancerous lesions and transmission to sexual partners

IV. Preparations: Gardasil

  1. Mixture of primary capsid proteins of 4 HPV types (Quadrivalent)
  2. Two low risk HPV types (but cause 90% of Genital Warts)
    1. HPV 6
    2. HPV 11
  3. Two high risk HPV types (cause 70% of Cervical Cancers)
    1. HPV 16
    2. HPV 18

V. Preparations: Gardasil-9

  1. Released in 2015 with additional coverage for 5 HPV antigens in addition to the 4 in the original Gardasil
    1. Replaces original Gardasil Vaccine
    2. Approved for females 9 to 26 years old and males 9 to 15 years old
    3. Improves coverage against Cervical Cancer causing HPV from 70% with Gardasil to 90% with Gardasil-9
    4. Gardasil-9 also reduces the risk of vulvar, vaginal and anal cancers when compared with Gardasil
    5. Gardasil-9 causes more local reactions than Gardasil (in which local reactions were already very common)
  2. Two low risk HPV types (but cause 90% of Genital Warts)
    1. HPV 6
    2. HPV 11
  3. Two high risk HPV types (cause 70% of Cervical Cancers)
    1. HPV 16
    2. HPV 18
  4. Additional HPV types responsible for cervical, vulvar, vaginal and anal cancers (added to Gardasil-9)
    1. HPV 31
    2. HPV 33
    3. HPV 45
    4. HPV 52
    5. HPV 58

VI. Preparations: Cervarix

  1. Human Papillomavirus Bivalent Vaccine
  2. Approved only for girls and women ages 9 to 25 years old
  3. Covers only two high risk types and none related to Genital Warts (contrast with Gardasil)
    1. HPV 16
    2. HPV 18

VII. Contraindications

  1. Pregnancy
  2. Anaphylaxis to yeast

VIII. Adverse Effects

  1. Local pain at injection site
    1. Gardasil: 84.9%
    2. Gardasil-9: 90.7%
  2. Local redness or swelling: 25%
  3. Fever
    1. Low grade in 10%
    2. Over 102 degrees in 1.4%
  4. Other reactions
    1. Syncope

IX. Efficacy

  1. Highest efficacy when administered prior to onset of sexual activity (prior to exposure)

X. Dosing

  1. Intramuscular Injection
  2. Original three dose schedule (age >15 years old)
    1. Schedule: 0, 2, and 6 months
    2. If one dose given before age 15 years old, may give a single booster dose age 15-26 years old
  3. New two dose schedule (2017)
    1. Schedule: 0 and 6-12 months apart
    2. Indicated for ages 9-14 years old (those >15 years old should use 3 dose schedules)
    3. First 2 doses must be at least 5 months apart (otherwise use 3 dose schedule)
    4. (2016) Presc Lett 23(12): 67

XI. Cost

  1. Three doses: >$1000 for Gardasil-9 (covered by most U.S. insurance plans)
    1. Original Gardasil was priced at >$400 for three doses

XIII. References

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Ontology: Human Papilloma Virus Vaccine (C1512511)

Definition (HL7V3.0) <p>human papilloma virus vaccine</p>
Definition (NCI_NCI-GLOSS) A vaccine used to prevent genital warts, cervical cancer, vulvar cancer, and vaginal cancer caused by certain types of human papillomavirus (HPV). It is also used to prevent lesions that are caused by those viruses and that can lead to cervical, vulvar, or vaginal cancer.
Definition (NCI) A recombinant vaccine of different types of HPV proteins which are well-conserved within types with a significant inter-type variation.
Concepts Immunologic Factor (T129) , Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
MSH D053918
SnomedCT 424519000, 423929007
HL7 62
English HPV Vaccines, Human Papilloma Virus Vaccines, Human Papillomavirus Vaccines, Papillomavirus Vaccines, Human, Vaccines, Human Papillomavirus, human papillomavirus vaccine, Human papillomavirus vaccine (product), Human papillomavirus vaccine, Human papillomavirus vaccine (substance), HPV vaccine, human papilloma virus vaccine (medication), human papilloma virus vaccine, HPV, Recombinant Human Papilloma Virus Vaccine, HPV Vaccine, Human Papilloma Virus Vaccine
German Humanes Papillomavirus-Impfstoffe, HPV-Vakzine, HPV-Impfstoffe, Humanes Papillomavirus-Vakzine
French Vaccins anti-HPV, Vaccins anti-papillomavirus humain, Vaccins antipapillomavirus humain
Spanish vacuna anti-papilomavirus humano, vacuna anti-papilomavirus humano (producto), vacuna anti-papilomavirus humano (sustancia), Vacunas contra el Papillomavirus Humano, vacuna anti-HPV, vacuna contra virus del papiloma humano, vacuna contra HPV
Czech lidský papilomavirus - vakcíny, HPV vakcíny
Portuguese Vacinas contra Papilomavírus Humano
Italian Vaccini contro il Papillomavirus umano, Vaccini contro il papilloma virus umano, Vaccini anti HPV

Ontology: Gardasil (C1721787)

Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSH C512720
English Merck brand of HPV quadrivalent vaccine, Gardasil